Archive

Topical non-steroidal cream approved by FDA for atopic dermatitis

Written by Christine Clark | 9 Jan 2025

Tapinarof 1% cream (Vtama) has been approved by the Food and Drug Administration (FDA) for the treatment of atopic dermatitis (AD, eczema) in adults and children of two… read more.

FDA approves Vtama (tapinarof) cream, 1%to treat atopic dermatitis – Organon

Written by Charlie King | 29 Dec 2024

Organon announced that the FDA has approved Vtama (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD)… read more.

Research shows medication effective in treatment of children with atopic dermatitis

Written by Charlie King | 9 Dec 2024

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms of moderate-to-severe atopic dermatitis (eczema) in young children whether or… read more.

Why do 1 in 10 Americans get eczema? Is it too much salt?

Written by Charlie King | 6 Jun 2024

UCSF Study finds that changes in daily salt intake may explain eczema flares. A high sodium diet may increase the risk of eczema, according to researchers at UC… read more.

New data show Rinvoq (upadacitinib) demonstrated superiority versus Dupixent (dupilumab) across primary and all secondary endpoints in an open-label head-to-head atopic dermatitis study – Abbvie

Written by Charlie King | 3 May 2024

AbbVie announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase IIIb/IV study that evaluated the efficacy and safety of upadacitinib (Rinvoq, 15 mg once… read more.

Atopic dermatitis: Viruses discovered as new therapy option

Written by Charlie King | 4 Oct 2023

Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching… read more.

Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis

Written by Charlie King | 19 Mar 2023

Two phase 3 trials suggest that a 16 week treatment with a drug called lebrikizumab was effective in adults and adolescents with moderate to severe dermatitis, according to… read more.

Do skin moisturizers help prevent eczema in infants?

Written by Charlie King | 24 Nov 2022

Atopic dermatitis (AD), also called atopic eczema, is the most common, chronic, recurrent, inflammatory disorder of the skin, and it affects 5–30% of children worldwide. An analysis in… read more.

Phase III ECZTEND long term study of Adbry shows consistency with other studies in atopic dermatitis – LEO Pharma

Written by Charlie King | 15 Apr 2022

LEO Pharma announced up to 3.5-year data that further support the long-term safety and efficacy profile of Adbry (tralokinumab-ldrm) in adult patients with moderate-to-severe atopic dermatitis (AD). The… read more.

FDA approves Opzelura cream for mild to moderate atopic dermatitis – Incyte

Written by Charlie King | 9 Oct 2021

Incyte announced that the FDA has approved Opzelura (ruxolitinib) cream for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12… read more.

Dupixent product characteristics updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis – Regeneron + Sanofi

Written by Charlie King | 8 Jul 2021

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Medicines Agency will update the Dupixent (dupilumab) summary of product characteristics (SmPC) adding long-term safety results for adults with… read more.

Archive

Subscribe for our mailing list

Follow Us